cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Curis Inc
50 own
49 watching
Current Price
$11.8
$-0.8
(-6.35%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
80.66M
52-Week High
52-Week High
17.49000
52-Week Low
52-Week Low
0.38000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization80.66M
icon52-Week High17.49000
icon52-Week Low0.38000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Curis Inc do?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Read More
How much money does Curis Inc make?
News & Events about Curis Inc.
PR Newswire
1 year ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., May 5, 2023 LEXINGTON, Mass., May 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the...
PR Newswire
1 year ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., April 5, 2023 LEXINGTON, Mass., April 5, 2023 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the...
PR Newswire
1 year ago
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call PR Newswire LEXINGTON, Mass., March 8, 2023 LEXINGTON, Mass., March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused...
Benzinga
1 year ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Curis Inc share price today?
plus_minus_icon
Can Indians buy Curis Inc shares?
plus_minus_icon
How can I buy Curis Inc shares from India?
plus_minus_icon
Can Fractional shares of Curis Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Curis Inc stocks?
plus_minus_icon
What is today’s traded volume of Curis Inc?
plus_minus_icon
What is today’s market capitalisation of Curis Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Curis Inc?
plus_minus_icon
What percentage is Curis Inc down from its 52-Week High?
plus_minus_icon
What percentage is Curis Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$11.8
$-0.8
(-6.35%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00